Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORRO...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Thorax
Year: 2018, Jahrgang: 73, Heft: 6, Pages: 581-583 |
| ISSN: | 1468-3296 |
| DOI: | 10.1136/thoraxjnl-2016-209701 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1136/thoraxjnl-2016-209701 Verlag, kostenfrei, Volltext: http://thorax.bmj.com/content/73/6/581 
|
| Verfasserangaben: | Luca Richeldi, Michael Kreuter, Moisés Selman, Bruno Crestani, Anne-Marie Kirsten, Wim A. Wuyts, Zuojun Xu, Katell Bernois, Susanne Stowasser, Manuel Quaresma, Ulrich Costabel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575818191 | ||
| 003 | DE-627 | ||
| 005 | 20220814151022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180529s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/thoraxjnl-2016-209701 |2 doi | |
| 035 | |a (DE-627)1575818191 | ||
| 035 | |a (DE-576)505818191 | ||
| 035 | |a (DE-599)BSZ505818191 | ||
| 035 | |a (OCoLC)1341010202 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Richeldi, Luca |e VerfasserIn |0 (DE-588)116026578X |0 (DE-627)1023418843 |0 (DE-576)505817535 |4 aut | |
| 245 | 1 | 0 | |a Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib |b results from the TOMORROW trial and its open-label extension |c Luca Richeldi, Michael Kreuter, Moisés Selman, Bruno Crestani, Anne-Marie Kirsten, Wim A. Wuyts, Zuojun Xu, Katell Bernois, Susanne Stowasser, Manuel Quaresma, Ulrich Costabel |
| 264 | 1 | |c 2018 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published Online First 9 October 2017 | ||
| 500 | |a Gesehen am 29.05.2018 | ||
| 520 | |a The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) in the nintedanib group and −189.7 mL/year (95% CI −229.8 to −149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks. | ||
| 650 | 4 | |a idiopathic pulmonary fibrosis | |
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 700 | 1 | |a Quaresma, Manuel |e VerfasserIn |0 (DE-588)1160266247 |0 (DE-627)1023419378 |0 (DE-576)505818094 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thorax |d London : BMJ Publishing Group, 1946 |g 73(2018), 6, Seite 581-583 |h Online-Ressource |w (DE-627)300184360 |w (DE-600)1481491-2 |w (DE-576)078941024 |x 1468-3296 |7 nnas |a Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib results from the TOMORROW trial and its open-label extension |
| 773 | 1 | 8 | |g volume:73 |g year:2018 |g number:6 |g pages:581-583 |g extent:3 |a Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib results from the TOMORROW trial and its open-label extension |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/thoraxjnl-2016-209701 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://thorax.bmj.com/content/73/6/581 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180529 | ||
| 993 | |a Editorial | ||
| 994 | |a 2018 | ||
| 998 | |g 1160266247 |a Quaresma, Manuel |m 1160266247:Quaresma, Manuel |d 910000 |d 950000 |d 950900 |e 910000PQ1160266247 |e 950000PQ1160266247 |e 950900PQ1160266247 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 10 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1575818191 |e 3010632630 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published Online First 9 October 2017","Gesehen am 29.05.2018"],"recId":"1575818191","person":[{"role":"aut","roleDisplay":"VerfasserIn","given":"Luca","display":"Richeldi, Luca","family":"Richeldi"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Michael","display":"Kreuter, Michael","family":"Kreuter"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Manuel","display":"Quaresma, Manuel","family":"Quaresma"}],"language":["eng"],"id":{"doi":["10.1136/thoraxjnl-2016-209701"],"eki":["1575818191"]},"name":{"displayForm":["Luca Richeldi, Michael Kreuter, Moisés Selman, Bruno Crestani, Anne-Marie Kirsten, Wim A. Wuyts, Zuojun Xu, Katell Bernois, Susanne Stowasser, Manuel Quaresma, Ulrich Costabel"]},"physDesc":[{"extent":"3 S."}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"relHost":[{"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"Thoracic Society"},{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"British Medical Association"}],"titleAlt":[{"title":"eThorax"}],"id":{"eki":["300184360"],"zdb":["1481491-2"],"issn":["1468-3296"]},"part":{"issue":"6","volume":"73","pages":"581-583","extent":"3","year":"2018","text":"73(2018), 6, Seite 581-583"},"recId":"300184360","note":["Gesehen am 09.02.09","Beteil. Körp. anfangs: British Medical Association"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1946 -"],"title":[{"subtitle":"an international journal of respiratory medicine ; official journal of the British Thoracic Society","title_sort":"Thorax","title":"Thorax"}],"language":["eng"],"disp":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib results from the TOMORROW trial and its open-label extensionThorax","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1946-","publisher":"BMJ Publishing Group","dateIssuedKey":"1946","publisherPlace":"London"}]}],"title":[{"subtitle":"results from the TOMORROW trial and its open-label extension","title":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib","title_sort":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib"}]} | ||
| SRT | |a RICHELDILULONGTERMTR2018 | ||